As multinational pharmaceutical companies accelerated the entry of innovative products into the Chinese market, Merck Sharp & Dohme approved another new drug for clinical trials

【Pharmaceutical Network Industry News】In recent years, innovative drugs are driving the rapid expansion of China's pharmaceutical market
.
In the face of this change, multinational pharmaceutical companies have begun to accelerate the pace of introducing more new drugs
to China.
On November 15, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that the MK-0616 capsules declared by Merck have obtained implied approval for clinical trials, and it is planned to develop the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
.
According to public information, MK-0616 is a new cholesterol-lowering drug, which is an oral PCSK9 inhibitor and has entered the phase 2 clinical research stage
overseas.
Phase 1 clinical trials showed that MK-0616 in combination with statins reduced blood levels of low-density lipoprotein cholesterol (LDL-C) by 65%.

It is understood that in recent years, Merck is actively deploying the Chinese market, and at the same time, it is constantly bringing more best-in-class, innovative drugs and therapies
.
In addition to MK-0616 capsules, on May 13 this year, according to the NMPA website, Merck's new antiviral drug letermovir injection dosage form has also been approved for marketing
.
Data show that the product has a new anti-CMV effect, by inhibiting the activity of CMV terminal enzyme complex, preventing the processing and packaging of viral DNA, thereby exerting antiviral effects
.
It is worth mentioning that the tablet dosage form of the drug has been approved in China in January this year for the preventive treatment of cytomegalovirus.
.
.
The Chinese market has always been an important market
in the global strategy of multinational pharmaceutical companies.
Statistics show that in 2021, China's pharmaceutical industry achieved revenue of 3.
37075 billion yuan, a new
high growth rate in the past five years.
Attracted by the huge market, many multinational pharmaceutical companies have indicated that the Chinese market will remain stable in the next 3 to 5 years in their global strategic importance
.
At the same time, more and more pharmaceutical companies are also gearing up to bring more innovative products to the Chinese market
.
For example, during this year's Expo, many multinational pharmaceutical companies brought a large number of new drugs to appear
.
Among them, AstraZeneca exhibited its first product in the field of rare diseases, eculizumab injection
.
This is a prescription drug
that has been approved in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and children.
Teva brought Titan, a product known to be used to treat Huntington's disease, commonly known as "chorea", a rare autosomal dominant neurodegenerative disease in which most patients experience involuntary dance-like movements
.
At present, Antaltan has passed the priority review and approval process and has been approved for listing in China and has entered the medical insurance catalog
.
Sanofi also brought a number of new rare disease drugs to the Expo, including the world's first approved nanobody drug Cablivi, which is the first targeted
treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
。 There is also a new generation of enzyme replacement therapy (ERT) drugs for Pompe disease, Nexviazyme, which has been granted "breakthrough therapy" designation by the FDA and is expected to greatly improve respiratory function and exercise capacity in patients with Pompe disease.
.
.
At present, many multinational pharmaceutical companies are trying to find more opportunities in the Chinese market by exploring innovative research and development, win-win cooperation, digital intelligence, etc.
, so in recent years, news of multinational pharmaceutical companies setting up factories in Chinese mainland and building R&D centers has also been frequently appearing
.
The industry believes that this fully proves its importance and optimism about the Chinese market, and will also bring more treatment options
for domestic patients in the future.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.